Longjiang She
Foshan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Cost-effectiveness analysis of sintilimab additional to chemoradiotherapy in high-risk locoregionally advanced nasopharyngeal carcinoma.
Journal: Frontiers in pharmacology
Published: December 20, 2024
Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis.
Journal: Cost effectiveness and resource allocation : C/E
Published: November 23, 2023
Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma.
Journal: Frontiers in immunology
Published: July 13, 2023
First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis.
Journal: Head & neck
Published: April 10, 2023
Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Journal: Frontiers in oncology
Published: March 25, 2022
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer.
Journal: Frontiers in oncology
Published: April 08, 2020
Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: February 29, 2020
Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Journal: Advances in therapy
Published: February 09, 2020
Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
Journal: The oncologist
Published: November 27, 2019
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 14, 2019
Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
Journal: Journal of medical economics
Published: February 28, 2019
Showing 1-12 of 12
Last Updated: 09/26/2026